comparemela.com

Latest Breaking News On - Esbla - Page 1 : comparemela.com

Surya Bhatt, MD: Findings on Dupilumab for Patients with COPD, Type 2 Inflammation

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

FDA Accepts sBLA for Priority Review of Dupilumab for Uncontrolled COPD

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC

The FDA granted priority review to a sBLA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC.

Australian businesses to pull back on borrowing and investing in 2024 – survey

Medium-sized businesses are more likely to tighten their budgets

AZ gets CRL asking for REMS changes to rare disease sBLA

While the U.S. FDA didn’t ask for more study data or have safety or efficacy concerns, it does want modifications to Alexion, Astrazeneca Rare Disease’s sBLA for Ultomiris (ravulizumab-cwvz) to treat adults with the rare central nervous system disease neuromyelitis optica spectrum disorder. The agency has issued a complete response letter (CRL) requesting changes to Ultomiris’ Risk Evaluation and Mitigation Strategy (REMS) to better validate patients’ meningococcal vaccination status or prophylactic administration of antibiotics before being treated.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.